Evolent Health (EVH) Stock Forecast & Price Target

Compare

714 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EVH Analyst Ratings

Strong Buy

10 Buy

0 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Evolent

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EVH Stock 12 Month Forecast

Average Price Target

$15.00

▲(50.30%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Evolent Health in the last 3 months. The average price target is $15.00 with a high forecast of $20.00 and a low forecast of $13.00. The average price target represents a 50.30% change from the last price of $9.98.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","19":"$19","32":"$32","12.5":"$12.5","25.5":"$25.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,12.5,19,25.5,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.98,10.750769230769231,11.521538461538462,12.292307692307693,13.063076923076924,13.833846153846155,14.604615384615386,15.375384615384615,16.146153846153847,16.916923076923077,17.68769230769231,18.45846153846154,19.229230769230767,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.98,10.366153846153846,10.752307692307692,11.138461538461538,11.524615384615386,11.910769230769231,12.296923076923077,12.683076923076923,13.069230769230769,13.455384615384617,13.841538461538462,14.227692307692308,14.613846153846154,{"y":15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.98,10.212307692307693,10.444615384615386,10.676923076923078,10.909230769230769,11.141538461538461,11.373846153846154,11.606153846153846,11.838461538461539,12.07076923076923,12.303076923076922,12.535384615384615,12.767692307692307,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.44,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.98,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.46,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.25,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.95,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$20.00

Average Price Target$15.00

Lowest Price Target$13.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$10

Hold

0.20%

Upside

Reiterated

07/19/25

Evolent Health's stock score is primarily driven by financial challenges and valuation concerns. Positive aspects include revenue growth, strategic initiatives, and financial flexibility from recent corporate actions. However, high leverage and profitability issues weigh heavily on the overall assessment.

Jailendra SinghTruist Financial

Truist Financial

―

Buy

―

Reiterated

08/01/25

Analysts Offer Insights on Healthcare Companies: Vericel (NASDAQ: VCEL), Evolent Health (NYSE: EVH) and CVS Health (NYSE: CVS)

Unknown AnalystCiti

Not Ranked

Citi

$13→$14

Buy

40.28%

Upside

Reiterated

07/28/25

Citi Sticks to Its Buy Rating for Evolent Health (EVH)

Charles RhyeeTD Cowen

TD Cowen

$14

Buy

40.28%

Upside

Reiterated

07/14/25

Evolent Health's Positive Outlook: Strong Q2 Performance and Promising Pipeline Growth Justify Buy Rating

Kevin CaliendoUBS

UBS

$15

Buy

50.30%

Upside

Reiterated

06/22/25

Evolent Health news Friday 'incrementally positive,' says UBSEvolent Health news Friday 'incrementally positive,' says UBS

Richard CloseCanaccord Genuity

Canaccord Genuity

$16

Buy

60.32%

Upside

Reiterated

06/20/25

Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), Evolent Health (EVH)

Constantine DavidesCitizens JMP

Citizens JMP

$13

Buy

30.26%

Upside

Reiterated

06/20/25

Evolent Health (EVH) Gets a Buy from Citizens JMP

Ryan DanielsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/14/25

Evolent Health: Buy Rating Affirmed on Positive Financial Adjustments and Growth Outlook

Matthew SheaNeedham

Needham

$15

Buy

50.30%

Upside

Reiterated

05/13/25

Analysts Offer Insights on Healthcare Companies: Evolent Health (NYSE: EVH), Xenon (NASDAQ: XENE) and Biohaven Ltd. (NYSE: BHVN)

Anne SamuelJ.P. Morgan

J.P. Morgan

$12→$13

Buy

30.26%

Upside

Reiterated

05/09/25

J.P. Morgan Sticks to Its Buy Rating for Evolent Health (EVH)

Matthew Gillmor CFAKeyBanc

KeyBanc

$20

Buy

100.40%

Upside

Reiterated

05/09/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alector (NASDAQ: ALEC), Evolent Health (NYSE: EVH) and Theriva Biologics (NYSE MKT: TOVX)

Michael WiederhornOppenheimer

Oppenheimer

$18

Buy

80.36%

Upside

Reiterated

02/21/25

Oppenheimer Remains a Buy on Evolent Health (EVH)We are tweaking our FY25/26/27 EPS estimates to $0.42/$0.59/$0.77 from $0.60/$0.79/$1.00.

Jessica TassanPiper Sandler

Piper Sandler

$17→$16

Buy

60.32%

Upside

Reiterated

02/21/25

Evolent Health price target lowered to $16 from $17 at Piper SandlerEvolent Health price target lowered to $16 from $17 at Piper Sandler

David LarsenBTIG

BTIG

$20

Buy

100.40%

Upside

Reiterated

02/21/25

Analysts Conflicted on These Healthcare Names: Glaukos (NYSE: GKOS), Danaher (NYSE: DHR) and Evolent Health (NYSE: EVH)

Jeffrey GarroStephens

Stephens

$16→$12

Hold

20.24%

Upside

Reiterated

01/21/25

Evolent Health price target lowered to $12 from $16 at StephensEvolent Health price target lowered to $12 from $16 at Stephens

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$10

Hold

0.20%

Upside

Reiterated

07/19/25

Jailendra SinghTruist Financial

Truist Financial

―

Buy

―

Reiterated

08/01/25

Analysts Offer Insights on Healthcare Companies: Vericel (NASDAQ: VCEL), Evolent Health (NYSE: EVH) and CVS Health (NYSE: CVS)

Unknown AnalystCiti

Not Ranked

Citi

$13→$14

Buy

40.28%

Upside

Reiterated

07/28/25

Citi Sticks to Its Buy Rating for Evolent Health (EVH)

Charles RhyeeTD Cowen

TD Cowen

$14

Buy

40.28%

Upside

Reiterated

07/14/25

Evolent Health's Positive Outlook: Strong Q2 Performance and Promising Pipeline Growth Justify Buy Rating

Kevin CaliendoUBS

UBS

$15

Buy

50.30%

Upside

Reiterated

06/22/25

Evolent Health news Friday 'incrementally positive,' says UBSEvolent Health news Friday 'incrementally positive,' says UBS

Richard CloseCanaccord Genuity

Canaccord Genuity

$16

Buy

60.32%

Upside

Reiterated

06/20/25

Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), Evolent Health (EVH)

Constantine DavidesCitizens JMP

Citizens JMP

$13

Buy

30.26%

Upside

Reiterated

06/20/25

Evolent Health (EVH) Gets a Buy from Citizens JMP

Ryan DanielsWilliam Blair

William Blair

―

Buy

―

Reiterated

05/14/25

Evolent Health: Buy Rating Affirmed on Positive Financial Adjustments and Growth Outlook

Matthew SheaNeedham

Needham

$15

Buy

50.30%

Upside

Reiterated

05/13/25

Analysts Offer Insights on Healthcare Companies: Evolent Health (NYSE: EVH), Xenon (NASDAQ: XENE) and Biohaven Ltd. (NYSE: BHVN)

Anne SamuelJ.P. Morgan

J.P. Morgan

$12→$13

Buy

30.26%

Upside

Reiterated

05/09/25

J.P. Morgan Sticks to Its Buy Rating for Evolent Health (EVH)

Matthew Gillmor CFAKeyBanc

KeyBanc

$20

Buy

100.40%

Upside

Reiterated

05/09/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alector (NASDAQ: ALEC), Evolent Health (NYSE: EVH) and Theriva Biologics (NYSE MKT: TOVX)

Michael WiederhornOppenheimer

Oppenheimer

$18

Buy

80.36%

Upside

Reiterated

02/21/25

Oppenheimer Remains a Buy on Evolent Health (EVH)We are tweaking our FY25/26/27 EPS estimates to $0.42/$0.59/$0.77 from $0.60/$0.79/$1.00.

Jessica TassanPiper Sandler

Piper Sandler

$17→$16

Buy

60.32%

Upside

Reiterated

02/21/25

Evolent Health price target lowered to $16 from $17 at Piper SandlerEvolent Health price target lowered to $16 from $17 at Piper Sandler

David LarsenBTIG

BTIG

$20

Buy

100.40%

Upside

Reiterated

02/21/25

Analysts Conflicted on These Healthcare Names: Glaukos (NYSE: GKOS), Danaher (NYSE: DHR) and Evolent Health (NYSE: EVH)

Jeffrey GarroStephens

Stephens

$16→$12

Hold

20.24%

Upside

Reiterated

01/21/25

Evolent Health price target lowered to $12 from $16 at StephensEvolent Health price target lowered to $12 from $16 at Stephens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Evolent Health

1 Month

xxx

Success Rate

24/45 ratings generated profit

Average Return

+0.80%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +0.80% per trade.

3 Months

xxx

Success Rate

25/45 ratings generated profit

Average Return

+2.76%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +2.76% per trade.

1 Year

Richard CloseCanaccord Genuity

Success Rate

21/45 ratings generated profit

Average Return

+13.87%

reiterated a buy rating 2 months ago

Copying Richard Close's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of +13.87% per trade.

2 Years

xxx

Success Rate

18/45 ratings generated profit

Average Return

+21.55%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of +21.55% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EVH Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EVH has received 10 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. EVH average Analyst price target in the past 3 months is 15.00.

Each month's total comprises the sum of three months' worth of ratings.

EVH Financial Forecast

EVH Earnings Forecast

Next quarter’s earnings estimate for EVH is $0.07 with a range of $0.00 to $0.15. The previous quarter’s EPS was $0.06. EVH beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.15% of the time in the same period. In the last calendar year EVH has Preformed in-line its overall industry.

EVH Sales Forecast

Next quarter’s sales forecast for EVH is $459.56M with a range of $447.22M to $468.00M. The previous quarter’s sales results were $483.65M. EVH beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.33% of the time in the same period. In the last calendar year EVH has Preformed in-line its overall industry.

EVH Stock Forecast FAQ

What is EVH’s average 12-month price target, according to analysts?

Based on analyst ratings, Evolent Health’s 12-month average price target is 15.00.

What is EVH’s upside potential, based on the analysts’ average price target?

Evolent Health has 50.30% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EVH a Buy, Sell or Hold?

Evolent Health has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.

What is Evolent Health’s price target?

The average price target for Evolent Health is 15.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $20.00 ,the lowest forecast is $13.00. The average price target represents 50.30% Increase from the current price of $9.98.

What do analysts say about Evolent Health?

Evolent Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of EVH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Evolent Health (EVH) Stock Forecast & Price Target

EVH Analyst Ratings

EVH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Evolent Health

EVH Analyst Recommendation Trends

EVH Financial Forecast

EVH Earnings Forecast

EVH Sales Forecast

EVH Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts